Mutamycin Articles

FDA accuses Sanofi of using misleading article

15 May 2009

Lack of important developments in the European bladder cancer market: F&S

15 October 2007

Myriad to investigate pancreatic cancer diagnostic

30 October 2006

Supergen sells US Nipent rights to Mayne

3 July 2006

Halozyme gets US OK for Chemophase trial

22 August 2005

Halozyme submits IND for Chemophase

11 July 2005

Fruit and veg extract enhances cancer drug

11 October 2004

Extended Indications For R-PR's Taxotere

25 June 1998

Expanded Use Of R-PR's Taxotere Backed

4 June 1998

Taxol, Platinum "Optimal" For Ovarian Cancer

27 May 1998

SuperGen Begins Mitomycin Franchise

11 May 1998

SuperGen's MitoExtra Accepted For FDA Review

26 February 1998

Taxotere "Superior To Adriamycin"

8 December 1997

Taxotere Outperforms Standard Drugs In Breast Cancer

30 May 1997

Investment, Profitability And Biotechnology

14 October 1996

Australia Approves US Bioscience's Ethyol

16 September 1996

SuperGen's Mitomycin C

19 February 1996

Sandoz MDR Drug Shows Promise In Early Trials

13 November 1995

First European Approval For Lilly's Gemzaar

22 May 1995

New Anticancer Agents: Phase II Trial Results

12 December 1994

Lilly's Gemcitabine; First Phase III Results

28 November 1994

Anticancer Drugs In Development In Japan

24 October 1994

Theratope Preliminary Phase II Results

26 September 1994

KYOWA HAKKO'S MITOMYCIN

5 April 1993

NEW CANCER DRUGS SHINE AT US MEETING

2 November 1992

Showing 1-25 of 25 articles

Go to beginningPrevious
  • 1
NextGo to end